Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUVENAL E MARTINEZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1558459529
CMS profile
69926
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,687.36

46 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $937.99 43
Travel and Lodging $749.37 3

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–46 of 46 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUVENAL E MARTINEZ

NPI 1558459529 · CMS profile ID 69926

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–46 of 46 matching records. This page contains 46 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558459529?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–46 of 46 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558459529?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–46 of 46 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558459529?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–46 of 46 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1558459529?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

46 matching records · $1,687.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 46 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–46 of 46.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $13.1312/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031801261 CMS
Novo Nordisk Inc $23.3311/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000720381 CMS
Novo Nordisk Inc $23.3411/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000720389 CMS
Lilly USA, LLC $24.8511/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031895659 CMS
Lilly USA, LLC $14.0011/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031869161 CMS
Amgen Inc. $16.0311/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020612401 CMS
Exact Sciences Corporation $22.8211/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026546197 CMS
UCB, Inc. $60.6110/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022002179 CMS
UCB, Inc. $86.2010/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022002183 CMS
UCB, Inc. $154.3210/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022002187 CMS
UCB, Inc. $252.7010/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022002191 CMS
UCB, Inc. $342.3510/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022002195 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.5310/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997010361 CMS
Lilly USA, LLC $13.1310/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031846601 CMS
Medtronic, Inc. $30.3409/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025949215 CMS
PFIZER INC. $20.0009/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050481405 CMS
Exact Sciences Corporation $22.9208/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026546165 CMS
Amneal Pharmaceuticals LLC $16.5308/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053514903 CMS
Astellas Pharma US Inc $18.4508/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034443105 CMS
Lilly USA, LLC $14.0008/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031869159 CMS
Lilly USA, LLC $13.4607/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031746348 CMS
Abbott Laboratories $22.1907/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019575621 CMS
Lilly USA, LLC $13.1307/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031735301 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.7905/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997010363 CMS
Abbott Laboratories $56.9505/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019573191 CMS
Abbott Laboratories $22.0205/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018482665 CMS
Lilly USA, LLC $14.0005/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031895671 CMS
AstraZeneca Pharmaceuticals LP $17.3805/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014566927 CMS
Novo Nordisk Inc $24.6905/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000720399 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.3004/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997010365 CMS
Amgen Inc. $18.5204/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020612399 CMS
AstraZeneca Pharmaceuticals LP $18.9704/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011370947 CMS
Lilly USA, LLC $21.9004/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031735307 CMS
Exact Sciences Corporation $23.1404/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026546131 CMS
Lilly USA, LLC $13.1303/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031729591 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.9803/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000100315 CMS
Novo Nordisk Inc $24.9603/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000720407 CMS
AstraZeneca Pharmaceuticals LP $20.3403/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014550021 CMS
IDORSIA PHARMACEUTICALS US INC $20.7203/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034475947 CMS
Lilly USA, LLC $0.3103/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031735295 CMS
Lilly USA, LLC $13.3803/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031869155 CMS
Amgen Inc. $14.0602/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020612397 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.5502/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000143961 CMS
Lilly USA, LLC $11.6702/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031895665 CMS
Lilly USA, LLC $14.0001/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031746343 CMS
Axsome Therapeutics, Inc. $22.2401/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056171229 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,824.81 72
PY2020 $1,108.16 66
PY2021 $1,714.64 78
PY2022 $1,279.40 50
PY2023 $1,687.36 46
PY2024 $1,313.52 50
PY2025 $665.19 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,400.63 16
PY2025 Principal investigator $701,734.65 46
PY2024 Principal investigator $1,015,383.57 140
PY2023 Principal investigator $1,037,707.93 416
PY2022 Principal investigator $88,070.01 24
PY2021 Principal investigator $334,298.45 64
PY2020 Principal investigator $148,277.65 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 H. Lundbeck A S $4,306.25 12/09/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090553
Principal investigator 1 H. Lundbeck A S $3,162.50 12/02/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090507
Principal investigator 1 H. Lundbeck A S $142.99 12/02/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090511
Principal investigator 1 H. Lundbeck A S $450.00 12/02/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090513
Principal investigator 1 H. Lundbeck A S $1,987.50 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090443
Principal investigator 1 H. Lundbeck A S $485.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090445
Principal investigator 1 H. Lundbeck A S $2,015.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090451
Principal investigator 1 H. Lundbeck A S $600.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090453
Principal investigator 1 H. Lundbeck A S $600.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090455
Principal investigator 1 H. Lundbeck A S $150.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090457
Principal investigator 1 H. Lundbeck A S $375.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090459
Principal investigator 1 H. Lundbeck A S $178.75 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090461
Principal investigator 1 H. Lundbeck A S $690.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090463
Principal investigator 1 H. Lundbeck A S $825.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090465
Principal investigator 1 H. Lundbeck A S $657.99 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090467
Principal investigator 1 H. Lundbeck A S $166.25 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090469
Principal investigator 1 H. Lundbeck A S $153.75 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090471
Principal investigator 1 H. Lundbeck A S $142.99 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090475
Principal investigator 1 H. Lundbeck A S $975.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090477
Principal investigator 1 H. Lundbeck A S $540.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090479
Principal investigator 1 H. Lundbeck A S $453.75 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090481
Principal investigator 1 H. Lundbeck A S $1,200.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090483
Principal investigator 1 H. Lundbeck A S $1,325.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090485
Principal investigator 1 H. Lundbeck A S $640.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090487
Principal investigator 1 H. Lundbeck A S $375.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090489
Principal investigator 1 H. Lundbeck A S $307.50 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090491
Principal investigator 1 H. Lundbeck A S $1,350.00 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090493
Principal investigator 1 H. Lundbeck A S $1,215.98 11/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090495
Principal investigator 1 H. Lundbeck A S $2,587.50 11/18/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090403
Principal investigator 1 H. Lundbeck A S $2,200.00 11/11/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090389
Principal investigator 1 H. Lundbeck A S $2,381.25 11/03/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,769.00 11/02/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816773159
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,251.29 11/02/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816773167
Principal investigator 1 H. Lundbeck A S $3,181.25 10/27/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090345
Principal investigator 1 H. Lundbeck A S $1,800.00 10/13/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090269
Principal investigator 1 H. Lundbeck A S $825.00 10/07/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090229
Principal investigator 1 H. Lundbeck A S $1,775.00 09/30/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090187
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,447.30 09/29/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816762333
Principal investigator 1 H. Lundbeck A S $3,612.50 09/16/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090159
Principal investigator 1 H. Lundbeck A S $3,293.75 09/09/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090135
Principal investigator 1 H. Lundbeck A S $1,325.00 09/02/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090125
Principal investigator 1 H. Lundbeck A S $5,137.50 08/26/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090113
Principal investigator 1 H. Lundbeck A S $2,675.00 08/06/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090075
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,767.40 07/27/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816746910
Principal investigator 1 H. Lundbeck A S $10,287.50 07/22/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090025
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,624.00 06/29/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816736311
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,691.50 06/29/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816736321
Principal investigator 1 H. Lundbeck A S $2,275.00 06/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 1179405814
Principal investigator 1 H. Lundbeck A S $2,275.00 06/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853089975
Principal investigator 1 H. Lundbeck A S $12,175.00 05/26/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 1179405666
Principal investigator 1 H. Lundbeck A S $12,175.00 05/26/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853089869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,045.00 05/25/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816728213
Principal investigator 1 H. Lundbeck A S $8,431.25 04/28/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 1179405598
Principal investigator 1 H. Lundbeck A S $8,431.25 04/28/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853089785
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $43,261.00 04/27/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816717447
Principal investigator 1 H. Lundbeck A S $4,812.50 04/01/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 1179405530
Principal investigator 1 H. Lundbeck A S $4,812.50 04/01/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853089659
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,135.09 03/30/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816704263
Principal investigator 1 H. Lundbeck A S $7,937.50 03/19/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853089565
Principal investigator 1 H. Lundbeck A S $18,812.50 02/24/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853089445
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,552.40 02/23/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816692237
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,969.50 02/02/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816686489
Principal investigator 1 H. Lundbeck A S $18,268.75 01/27/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853089265
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,826.27 01/26/2021 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816685589